WHO WE ARE
Innately Innovative
At Porton Advanced Solutions, we are committed to accelerating delivery of life-changing advanced therapies to patients. As a Advanced Therapy Medicinal Products CRO and CDMO company, we provide end-to-end biopharma solutions and services to our clients throughout the development and commercialization of their therapeutics
Our goal is to improve availability and commercial viability of these life-changing treatments by accelerating therapeutic development through our unique, innovative approach.
Porton Advanced Solutions is a subsidiary of the leading CDMO Porton Pharma Solutions. Porton Pharma Solutions is globally recognized and trusted for its process innovation, supply chain performance and compliance with global quality and EHS standards.
Expertise tailored to your needs
Our clients include a wide range of biotech and pharmaceutical companies, academic research institutes, and hospitals, each with unique needs spanning across discovery research, drug development, different clinical phases, and commercialization.
Our innovative, integrated approach enables us to respond to the full needs of each individual customer. We provide end-to-end biopharma solutions according to each client’s needs across multiple therapeutic platforms.
Dedicated, end-to-end support
We have been investing heavily in platform development across the ATMP and Chemistry, Manufacturing, and Control (CMC) spaces.
Our dedicated process and analytical development teams have built up proprietary technologies for client’s licenses and robust platform-based USP/DSP tailored to client’s manufacturing needs.
Our services include gene and cell engineering discovery research and technology licensing, process development and analytical development, testing, drug substances (DS) and drug products (DP), and cGMP manufacturing across plasmids, cell engineering, virotherapy, and mRNA-based therapeutic platforms.
Quality Assured
We adhere to strict control and assurance measures throughout to ensure we deliver exceptional quality products.
Latest News
Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy
Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
Porton Advanced Supports Immunofoco’s Second IND Clearance from China’s CDE for EpCAM CAR-T Therapy in Solid Tumors